Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07094932 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBD09
A Phase 1 study, sponsored by Gates Medical Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT07094932 is a Phase 1 study that has completed, run by Gates Medical Research Institute. The registered enrollment target is 36 participants.
The verdict
NCT07094932, a Phase 1 study, has completed, sponsored by Gates Medical Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, multiple dose trial of TBD09, administered to healthy adult participants to assess safety, tolerability, and pharmacokinetics up to 84 days of fixed daily dosing of TBD09. The trial will be conducted with two cohorts, with participants enrolled in parallel and randomized to receive either TBD09 or placebo.
Interventions
- DRUG Placebo
- DRUG TBD09
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-09-03 |
| Est. Completion | 2026-01-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07094932
The ClinicalTrials.gov registry entry for NCT07094932 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gates Medical Research Institute, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07094932 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07094932 about?
NCT07094932 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TBD09". This is a randomized, double-blind, placebo-controlled, multiple dose trial of TBD09, administered to healthy adult participants to assess safety, tolerability, and pharmacokinetics up to 84 days of fixed daily dosing of TBD09. The trial will be conducted with two cohorts, with participants enrolled...
What is the current status of trial NCT07094932?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2025-09-03. Estimated completion is 2026-01-11.
What interventions are being tested in trial NCT07094932?
The interventions under investigation include: Placebo (DRUG), TBD09 (DRUG).
Who is sponsoring clinical trial NCT07094932?
This trial is sponsored by Gates Medical Research Institute, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.